RICHARD TAN: Open Payments
NPI 1548936602 · ALHAMBRA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$994 in 50 payments from 12 companies in 2025. Trend: 2023 $282 · 2024 $973 · 2025 $994
Food & beverage: $994
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $290 |
| Amgen Inc. | 27 | $280 |
| Novo Nordisk Inc | 2 | $141 |
| Dexcom, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Merck Sharp & Dohme LLC | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 2 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
Products named: OTEZLA, AIRSUPRA, Ozempic, BREZTRI, Dexcom G6 Transmitter, REXULTI, LEQVIO, JARDIANCE.
Industry payments across CA — which companies pay providers there.
